GSK headquarters in London, UK. © Ian Wilson/Flickr. com

GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.

© NCI

A 3D tumour model developed by scientists enables drug screening in metastases

© Affimed NV

Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.

Microglia cells expressing the WENV protein. © Gregor Wicher, wikimedia.com

Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.


© Catalent

Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.

© Quince

AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.

© Bayer Leverkusen

German Bayer AG has announced  it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.

 

Projection of Avantium's FDCA plant. © Avantium NV

Avantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.

CT scan. © Mitrey/pixabay.com

Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad 

IgM antibodies have higher affinity and avidity due to their 10 binding sites versus only 2 binding sites of IgG antibodies. © IGM Bioscience Inc.

Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.